Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Prostate and Urologic Cancer Research Group

Programs and Projects

Prostate Cancer Clinical Trials - University of California, San Francisco

Agent: Lycopene or Omega-3 fatty acid
Contact: Peter Carroll, MD
DCP Program Director: Howard Parnes, MD

The purpose of this study is to see if there is a change in gene expression in prostate tissue in men who have chosen "watchful waiting" rather than surgery or radiation therapy. Patients will receive lycopene, Omega-3 fatty acid supplementation or placebo for 3 months. Researchers will compare the change in gene expression in prostate biopsies taken before and after study medication. The investigator is actively accruing participants to this trial.

[This is a phase 2 randomized double-blind placebo controlled phase chemoprevention trial of lycopene, Omega-3 fatty acid or placebo in men managed by watchful waiting. The primary endpoint (s) are the change in gene expression pre- and post-intervention; the proportion of men with this outcome will be compared between intervention and placebo groups.]